



**For Immediate Release**

**CONTACT:** Carol Klimas 480-505-4527  
carolk@offmadisonave.com  
www.ProvistaLS.com

## **PROVISTA LIFE SCIENCES COMPLETES CLINICAL TRIALS ON NEW BLOOD TEST FOR EARLY DETECTION OF BREAST CANCER**

**Phoenix** (December 21, 2007) – Provista Life Sciences LLC (PLS), a diagnostic development and commercialization company, announced today it has successfully completed extensive clinical trials on a new blood test for the early detection of [breast cancer](#). The test is called the [BT Test™](#) and it is being made available to a select number of physicians in the Phoenix market as part of the company's initial market release. The BT Test, which stands for Biomarker Translation Test, is designed to assist physicians in making an earlier and more accurate diagnosis of breast cancer when used adjunctively with a mammogram.

"Now that we've successfully completed our clinical trials, we are making the BT Test available to a select group of local physicians in order to optimize the integration processes for physicians prescribing and administering the test," said William Gartner, Provista Life Sciences CEO. "Our goal is to help save more women's lives from this devastating disease. Once this initial process evaluation is complete, we expect to make the BT Test available throughout the entire Phoenix market, and expanding its availability to additional markets as lab capacity allows."

According to the National Cancer Institute, breast cancer kills more women than any other form of cancer. One out of every eight women will be diagnosed with breast cancer in her lifetime – yet when detected and treated in its early stages, there is a 96 percent survival rate. Provista Life Sciences is a strong proponent of early detection of breast cancer and recommends a combination of annual mammograms and the BT Test to help doctors more accurately diagnose breast cancer in its early stages, when life-saving treatment is most effective.

In clinical studies involving breast cancer-positive and non-breast cancer patients, the latter group being comprised of both healthy and benign breast condition patients, the BT Test demonstrated an accuracy of 88 percent (as defined by the area under the ROC Curve). The BT Test utilizes a proprietary algorithm to evaluate the levels and relationship of multiple, cancer associated protein biomarkers in blood serum. This data is coupled with a patient's personal medical profile to generate a comprehensive report designed to assist healthcare providers in making an earlier diagnosis of breast cancer. Provista Diagnostics, a Clinical Laboratory Improvements Amendment (CLIA) registered laboratory and a wholly owned subsidiary of Provista Life Sciences, is providing the laboratory services for the test.

Provista Life Sciences currently has 15 Phoenix area practitioners offering the test and participating in this initial process optimization effort. The company is encouraging other physicians in the Phoenix market to contact its offices (602-224-5500) should they wish to be added to this group.

Physicians and women interested in learning more details about the BT Test can log on to:  
[www.ProvistaLS.com/AboutBTTest.aspx](http://www.ProvistaLS.com/AboutBTTest.aspx).

# # #

### **About Provista Life Sciences**

Provista Life Sciences is a biotechnology diagnostics development and commercialization organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company's Web site at [www.ProvistaLS.com](http://www.ProvistaLS.com) or call 602-224-5500.